Novita Presents Additional Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at AACR IO Annual Meeting

-Results indicate that NP-G2-044 provides a novel therapeutic opportunity when combined with ICIs- NEW YORK, Feb. 25, 2025 /PRNewswire-PRWeb/ -- Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs...